Industrial Biocatalysis Patents: Who Leads, Where the Gaps Are 2026
- Filing peaked in 2018 at 10 records and has since flattened, with the 2022 midpoint back at the same level — this is a mature, not accelerating, filing field.
- No single assignee shows momentum in the latest full year, recent-year activity across the tracked leaders reads zero, which points to a lull rather than a runaway leader.
- C12P fermentation claims sit inside 50 of 83 records, while C08L polymer-matrix and C07H sugar/nucleic-acid framings appear in single digits — a visible gap for carrier and substrate claims.
What this dataset covers
This landscape tracks 83 patent families published between 2015 and mid-2026 that combine biocatalysis, enzymatic catalysis or industrial enzyme terminology with claim or description language on immobilized enzyme, enzyme engineering, biocatalytic process, cofactor regeneration or enzymatic synthesis, filtered to the core IPC classes for microbial and fermentation biocatalysis (C12N9/00, C12P7/00, C12N11). It is a narrow, claims-anchored slice of a much larger enzyme-technology corpus, built to surface who is actually claiming immobilization and process chemistry rather than who merely mentions enzymes in passing.
Filing activity concentrates around the mid-2010s peak and has not re-accelerated; publication lag of roughly 18 months means the final one to two years of the window will always look thinner than they eventually turn out to be.
Filing trend and technology composition
83 families sit across six receiving offices and eight IPC subclasses, with the claim density concentrated in two classes.
A flat filing curve since 2018
Filings rose to a peak of 10 in 2018, held near that level through the 2022 midpoint, and show no upward inflection toward the end of the window. Read the final one to two years as understated given publication lag rather than as a genuine drop-off.
Fermentation and microbial classes dominate
C12N (microorganisms and genetic engineering) appears in 76 of 83 records and C12P (fermentation and enzymatic synthesis) in 50, confirming this corpus is fundamentally about production-organism and process claims. Peptide/protein (C07K), detergent (C11D) and polymer (C08L) classes each carry a much smaller share, which is where adjacent, less-crowded claim territory sits.
Shares are the percentage of the 83 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Industrial Biocatalysis Technology Landscape with Eureka
This page is one run against one query. Ask Eureka your own question about industrial biocatalysis technology landscape and every answer comes back with the patent numbers behind it.
Try EurekaThe most-cited prior art in this space
An enzyme-polymer matrix
The application describes a bioreactor for catalytic conversion of a substrate to a product using an immobilized enzyme. The enzyme carries a histidine tag that binds to a nickel-nanoparticle-coated cellulose matrix housed inside the bioreactor, and the filing covers methods of producing products by enzymatic catalysis using that bioreactor.Filed by Stellenbosch University; published 2023-10-26.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | WO2008017483A2 | Spore surface displays of bioactive molecules | 39 |
| 2 | WO2005056808A2 | Immobilization of biocatalysts by template-directed silicate precipitation | 34 |
| 3 | CN1834240A | 固定化酶的丝素纳米颗粒及其制备方法 | 20 |
| 4 | US20050158837A1 | Immobilization of biocatalysts by template-directed silicate precipitation | 19 |
| 5 | US20030166177A1 | Solid-phase array-based biocatalytic transformations | 13 |
| 6 | CN105754985A | 一种酶-金属离子纳米复合物及其制备方法 | 12 |
| 7 | CN114317472A | 一种高立体选择性亚胺还原酶及其制备方法和应用 | 11 |
| 8 | CN108588153A | 一种氨基酸型表面活性剂的酶催化制备方法 | 6 |
| 9 | WO2003008619A1 | Transglycosylation of nucleosides by biocatalysis with immobilized and stabilized enzymes. | 6 |
| 10 | CN112921023A | 一种重组天冬氨酸裂解酶及高重复利用率用于制备R-3-氨基丁酸的方法 | 4 |
Citation counts are drawn from a searched corpus and skew toward older, foundational filings; treat them as a signal of influence rather than of current commercial relevance.
Patent titles are shown in the language they were filed in, not translated, so that each record stays verifiable against the original filing — a translated title will not match in Eureka or in any national register. Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the filing pattern signals
Three read-throughs matter for anyone deciding whether to file, license or design around in this space.
The field is not accelerating
The trend rose to 10 families in 2018 and the 2022 midpoint sits at the same level, with no later year exceeding it. That is consistent with a technology where core immobilization and cofactor-regeneration chemistry is largely staked out, and new filings are refinements rather than land-grabs.
Microbial and genetic-engineering claims dominate
Nine in ten records touch C12N, and 50 touch C12P fermentation claims. Detergent (C11D), polymer (C08L) and sugar/nucleic-acid (C07H) classes each carry a handful of records, marking them as adjacent rather than core — and comparatively open.
Foundational immobilization patents still anchor searches
The most-cited records date to the mid-2000s and cover spore-surface display and template-directed silicate precipitation for biocatalyst immobilization. Their citation counts reflect age and foundational status in the corpus, not that the underlying chemistry is still the frontier.
Filing is mostly solo, with a few tight pairings
Only 10 co-assignee pairs appear across the corpus, and the strongest pairing recurs at a handful of filings rather than dozens — this is a field of largely independent filers rather than dense joint-development networks.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to industrial biocatalysis technology landscape, with the prior art for and against each one.
Who is filing, and where the gate sits
No assignee in the tracked leader set shows filings in the latest year, which makes this a field to watch for re-entry rather than one with an active frontrunner right now.
A quiet period, not an exit
Every assignee named in the recent-momentum tracking shows zero filings in the latest year. Given the mid-2010s peak and the 18-month publication lag, this likely reflects filings still working through the pipeline rather than abandonment of the space.
One industrial pairing stands out
The strongest co-assignee relationship in the dataset ties an international enzyme producer to a silicone materials company, at six shared filings — a materials-plus-biocatalyst pairing worth watching for licensing or supply relationships.
University labs hold a real share of the corpus
Institutions including a German university, a French national research body and a US research pairing appear among the recent-momentum leaders, indicating this remains a field where academic groups patent alongside industrial players rather than licensing out early.
| Assignee | Recent year | YoY |
|---|---|---|
| Genencor International, Inc. | 0 | — |
| BIOC3 | 0 | — |
| Dow Corning Corporation | 0 | — |
| Bendwell Technologies Limited Partnership | 0 | — |
| Ruhr University Bochum | 0 | — |
| Centre National de la Recherche Scientifique (CNRS) | 0 | — |
| University of South Florida | 0 | — |
| WARD II DONALD E | 0 | — |
Where to take this analysis
The dataset points to specific next checks rather than a single conclusion.
Search the adjacent IPC classes directly
C08L, C07H and A61K each carry single-digit record counts here. A targeted search within those classes, rather than this corpus's core filters, will show whether that is genuine white space or just outside this search string's scope.
Explore adjacent classes in EurekaTrack the pipeline behind the zero-momentum reading
Zero recent-year filings across tracked leaders is consistent with publication lag rather than exit. Re-run the momentum view in six to twelve months as 2025-2026 filings clear publication.
Set up a filing alert in EurekaMap the enzyme-producer/materials-company pairing
The strongest co-assignee relationship in the corpus links an enzyme producer to a silicone materials firm. Pulling their joint filings in full would clarify whether this is a supply relationship, a joint venture, or licensed technology.
Review co-assignee detail in EurekaCommon questions on the industrial biocatalysis patent landscape
The dataset's tracked leaders include an international enzyme producer, a silicone materials company, and several university and research-institute filers including groups in Germany and France. None of these shows filings in the most recent tracked year, so the current leader set reflects historical filing volume through the mid-2010s peak rather than an active frontrunner today. Anyone evaluating this space should treat the ranking as a picture of accumulated claim position, not of who is filing right now.
Filing peaked at 10 families in 2018 and the 2022 midpoint sits at the same level, with no later year in the dataset exceeding that peak. That pattern reads as flat to declining rather than growing. Because publication typically lags filing by around 18 months, the final year or two in any such trend will always look artificially low, so a true read on the most recent period requires waiting for those filings to clear publication.
Microbial and genetic-engineering claims under IPC class C12N appear in 76 of the 83 records, and fermentation/enzymatic-synthesis claims under C12P appear in 50. That concentration means core immobilized-enzyme and cofactor-regeneration process chemistry is densely claimed. Adjacent classes covering peptides, detergents, polymers and sugar or nucleic-acid chemistry carry far fewer records, which is where less-contested claim territory tends to sit.
That filing, assigned to Stellenbosch University, claims a bioreactor using a histidine-tagged enzyme bound to a nickel-nanoparticle-coated cellulose matrix for catalytic conversion of a substrate to a product. It blocks that specific combination of tag chemistry, nanoparticle coating and cellulose carrier within a bioreactor context, not immobilized-enzyme bioreactors generally. Work using different carrier materials, different tag chemistries, or non-nickel binding approaches would sit outside its literal claim scope, though a full freedom-to-operate check should compare claim language directly rather than relying on the abstract.
The clearest gaps sit outside the two dominant classes: polymer-composition carriers (C08L), sugar and nucleic-acid substrate systems (C07H), and detergent-grade enzyme stabilization (C11D) each appear in only a handful of the 83 records. These are adjacent to, rather than central to, the heavily claimed fermentation and microbial-engineering core, making them reasonable areas to search first before committing to a filing strategy in the crowded core classes.
Research Industrial Biocatalysis Technology Landscape in depth with Eureka
Go past this page: query the whole industrial biocatalysis technology landscape corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.